Irampanel

Irampanel (INN, code name BIIR-561) is a drug which acts as a dual noncompetitive antagonist of the AMPA receptor and neuronal voltage-gated sodium channel blocker.^[1][2] It was under development by Boehringer Ingelheim for the treatment of acute stroke/cerebral ischemia but never completed clinical trials for this indication.^[3][4] Irampanel was also trialed, originally, for the treatment of epilepsy and pain, but these indications, too, were abandoned,^[1] and the drug was ultimately never marketed.

Irampanel

Clinical data
ATC code	None
Identifiers
IUPAC name N,N-Dimethyl-2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethanamine
CAS Number	206260-33-5
PubChem CID	3038472
ChemSpider	2302037
UNII	R2GZD7LMYX
ChEMBL	ChEMBL29741
CompTox Dashboard (EPA)	DTXSID30174647
Chemical and physical data
Formula	C18H19N3O2
Molar mass	309.369 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN(C)CCOc1ccccc1c2nc(no2)c3ccccc3
InChI InChI=1S/C18H19N3O2/c1-21(2)12-13-22-16-11-7-6-10-15(16)18-19-17(20-23-18)14-8-4-3-5-9-14/h3-11H,12-13H2,1-2H3 Key:QZULPCPLWGCGSL-UHFFFAOYSA-N